Quick Answer
Eton Pharmaceuticals, Inc. reported Operating Income of -$844.0 thousand for fiscal year 2025.
Eton Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$844.0K | +67.5% |
| 2024 | -$2.60M | -117.9% |
| 2023 | -$1.19M | +85.6% |
| 2022 | -$8.26M | -452.5% |
| 2021 | -$1.50M | +94.5% |
| 2020 | -$27.11M | -45.8% |
| 2019 | -$18.60M | -80.2% |
| 2018 | -$10.32M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.36M | -367.8% | +7.6% |
| June 30, 2025 | -$1.48M | +49.7% | -213.8% |
| March 31, 2025 | -$470.0K | +41.2% | -192.3% |
| September 30, 2024 | $509.0K | +192.9% | +117.3% |
| June 30, 2024 | -$2.94M | -175.6% | -266.9% |
| March 31, 2024 | -$800.0K | +68.4% | -46.0% |
| September 30, 2023 | -$548.0K | +81.1% | -114.1% |
| June 30, 2023 | $3.88M | +389.8% | +253.2% |
- Eton Pharmaceuticals, Inc. showed an increase of +67.5% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Eton Pharmaceuticals, Inc.’s operating income has grown by 91.8% (from -$10.32 million to -$844.0 thousand).
- The most recent figure is from Eton Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: